What Could Merck (MRK) Gain From Two Positive EU CHMP Opinions?
Merck Gets EU Recommendations for Welireg Kidney Cancer Combo, Enflonsia RSV Expansion
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Merck’s WELIREG Plus Lenvatinib For Treatment Of Advanced Renal Cell Carcinoma With Clear Cell Component; Final Decision Expected In Next Two Months
Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove
What Merck KGaA (MRK) Said on Its Q3 Earnings Call
Merck to Participate in the Jefferies Global Healthcare Conference in London
Merck (MRK) Could Be 7% Undervalued As MASH Trial Data Lifts Optimism
Merck Shares Rose Even As Profit Fell
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
INVA or MRK: Which Is the Better Value Stock Right Now?
Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet
Merck (MRK) Starts ENHANCE 3 COPD Trial As Cancer Drug Review Nears
Is Merck (MRK) Undervalued After Its Cancer Trial Wins?
Merck & Co., Inc. (MRK): A Top 10 Healthcare Stock to Buy Following the 2026 Democratic Midterm Sweep
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?
Business Development Supports Merck & Co.’s (MRK) Next Growth Chapter
Merck & Co. Stock: Is Wall Street Bullish or Bearish?
Is Cancer And HIV Trial Wins Altering The Investment Case For Merck (MRK)?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.